What records are connected here?
- Evidence lanes
- 1
- Source years
- 2
- Drugs@FDA applications
- 0
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Not FDA-approved1,3Evidence: Animal and lab onlyTissue repair and wound healing
FOXO4-DRI is a lab-designed peptide, made of mirror-image (D) amino acids in reversed sequence, that blocks the FOXO4 protein from holding on to p53 inside ageing, or senescent, cells.1 In a 2017 mouse study it caused senescent cells to die and restored fitness, fur density and kidney function in old and fast-ageing mice; later mouse studies have tested it in other tissues.1,2 No study in people and no FDA approval are reported in the sources reviewed here, and it is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.1,3,5
| What it is | A synthetic D-retro-inverso peptide based on part of the FOXO4 protein, designed to disrupt its interaction with p53, according to the 2017 report that introduced it.1 |
|---|---|
| FDA status | No FDA approval is reported in the sources reviewed here. FDA’s compounding safety-risk page does not list it.1,3 |
| Human evidence | None found: the studies reviewed here used cells and mice.1,2 |
| Evidence strength | Animal and lab studies only. The cited sources report no completed human study; the research base consists of animal, cell, or other laboratory work. How this label is assigned |
FOXO4-DRI is a synthetic peptide designed by researchers who reported it in 2017. It copies a part of the FOXO4 protein, but uses D-amino acids, the mirror images of natural amino acids, in reversed sequence, a D-retro-inverso design that the authors note can improve a peptide’s potency.1
The 2017 report states that its sequence also carries a cell-entry tag derived from HIV-TAT.1
Senescent cells are damaged cells that avoid dying. The 2017 study found that FOXO4 helps keep them alive by holding p53, and that FOXO4-DRI disrupts this hold, pushing p53 out of the nucleus and triggering the cells’ own death program.1
A 2020 study in testosterone-producing Leydig cells found the same effect, describing FOXO4-DRI as a specific FOXO4 blocker.2
None of the sources reviewed here describes a study of FOXO4-DRI in people. The 2017 study used human cells in culture and mice.1
In mice, under conditions where it was well tolerated, it neutralized toxicity from the chemotherapy drug doxorubicin and restored fitness, fur density and kidney function in naturally aged and fast-ageing mice.1
In naturally aged mice, it improved the testicular environment and eased an age-related shortfall in testosterone, according to the 2020 study.2
Evidence-strength label: Animal and lab studies only. How this label is assigned
None of the sources reviewed here reports an approval of FOXO4-DRI by FDA.1,3
FDA’s compounding safety-risk page, current as of April 22, 2026, does not list FOXO4-DRI.3
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. FOXO4-DRI is not among them.4,5
Whether it has any of these effects in people, and whether it is safe: the studies reviewed here used cells and mice.1,2
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for FOXO4-DRI: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for FOXO4-DRI are a bounded selection, not every registration or paper about FOXO4-DRI. For the years before FOXO4-DRI was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list FOXO4-DRI as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name FOXO4-DRI in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
No FDA approval reported; studied only in cells and animals. Evidence comes from cell and mouse studies. FOXO4-DRI is not on FDA’s compounding safety-risk page and is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗
Status sources checked through November 14, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
No FDA approval reported; studied only in cells and animals. Evidence comes from cell and mouse studies. FOXO4-DRI is not on FDA’s compounding safety-risk page and is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗
The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Literature metadata · source date July 4, 2025
The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI.↗Added to PeptideScanner November 16, 2026Literature metadata · added November 16, 2026
The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI.↗Source date July 4, 2025Literature metadata · added November 16, 2026
Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes.↗Source date February 1, 2022PeptideScanner currently has no selected clinical trial records, regulatory records, and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
0 of 0 selected trial records include at least one phase value; 0 of 0 include a status value in the retained structured contract.
2 of 2 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
PubMed lists PMID 33996787 in Frontiers in bioengineering and biotechnology as Journal Article, with publication-date metadata of 2021-04-29 (day precision). PeptideScanner associated the retained record with the identity slug foxo4-dri. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 40593617 in Nature communications as Journal Article, with publication-date metadata of 2025-07-01 (day precision). PeptideScanner associated the retained record with the identity slug foxo4-dri. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
2 with attributed title, venue, publication-date, and type metadata.
Selected records span February 1, 2022 to July 4, 2025. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Literature metadata
PubMed lists PMID 40593617 in Nature communications as Journal Article, with publication-date metadata of 2025-07-01 (day precision). PeptideScanner associated the retained record with the identity slug foxo4-dri. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 33996787 in Frontiers in bioengineering and biotechnology as Journal Article, with publication-date metadata of 2021-04-29 (day precision). PeptideScanner associated the retained record with the identity slug foxo4-dri. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
Cell · Official source · Source checked November 16, 2026
Aging · Official source · Source checked November 16, 2026
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026